TAO kinase 3Genealiases: DPK · JIK · MAP3K18 · hKFC-A
Q-omics provides the consensus-scored TAOK3 profile across patient tissues and cancer cell-line models. TAOK3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAOK3 is differentially expressed in 17, with the highest sampling consensus in LIHC. Additionally, TAOK3 protein abundance shows 23,241 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LIHC, and LSCC as cancer lineages where TAOK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAOK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAOK3 survival associations across molecular data types. TAOK3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAOK3 RNA expression–survival associations across cancer types. High TAOK3 expression shows unfavorable associations in MESO, UVM, LUSC, ESCA and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAOK3 RNA expression.
This table summarizes TAOK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TAOK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAOK3 shows lower tumor expression in LUSC, THCA and UCEC and higher tumor expression in LIHC, HNSC and STAD. The LIHC box plot shows higher TAOK3 RNA expression in tumor versus normal tissue (log2 FC = +0.701, t-test p < 0.001).
This table shows molecular features associated with TAOK3 in patient tissues and cancer cell lines. In patient samples, TAOK3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAOK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
